Mirum tees up Livmarli label expansion on Phase III liver disease study success

Phase 3positiveLivmarliPositive

AI Analysis

Summary

Mirum Pharmaceuticals reported positive Phase III trial results for Livmarli in ultra-rare liver diseases including biliary atresia, positioning the drug for potential FDA label expansion in the United States.

Clinical Trial Data

Phase

Phase III

Primary Endpoint

Met

Outcome Details

Phase III liver disease study showed success

Importance:7/10

Sentiment:

0.70

Phase IIIlabel expansionrare diseaseliver diseaseFDA approval pending

Related Companies

$TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on October 12, 2026 2:48 PM

Read Original